One previous study about SUMO-1 gene therapy demonstrated that SUMO-1 modification of cardiac SERCA2a increases its activity and improves cardiac contractility in heart failure (Changwon et al., 2012; Tilemann et al., 2013). The gene discussed is SUMO1; the disease is heart failure.